MXPA05013121A - Derivados de indol con efecto de induccion de apoptosis. - Google Patents

Derivados de indol con efecto de induccion de apoptosis.

Info

Publication number
MXPA05013121A
MXPA05013121A MXPA05013121A MXPA05013121A MXPA05013121A MX PA05013121 A MXPA05013121 A MX PA05013121A MX PA05013121 A MXPA05013121 A MX PA05013121A MX PA05013121 A MXPA05013121 A MX PA05013121A MX PA05013121 A MXPA05013121 A MX PA05013121A
Authority
MX
Mexico
Prior art keywords
indole derivatives
apoptosis
inducing effect
medicaments
inducing
Prior art date
Application number
MXPA05013121A
Other languages
English (en)
Inventor
Eckhard Gunther
Original Assignee
Zentaris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP03012868A external-priority patent/EP1484329A1/de
Priority claimed from EP04011598A external-priority patent/EP1595878A1/de
Application filed by Zentaris Gmbh filed Critical Zentaris Gmbh
Publication of MXPA05013121A publication Critical patent/MXPA05013121A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invencion se refiere a derivados de indol usados como medicamentos para el tratamiento de enfermedades de tumor, de manera particular en el caso de resistencia de medicamentos contra otros ingredientes activos y carcinoma en metastasis.
MXPA05013121A 2003-06-05 2004-05-25 Derivados de indol con efecto de induccion de apoptosis. MXPA05013121A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US47627703P 2003-06-05 2003-06-05
EP03012868A EP1484329A1 (de) 2003-06-06 2003-06-06 Indolderivate mit Apoptose induzierender Wirkung
EP04011598A EP1595878A1 (de) 2004-05-15 2004-05-15 Indolderivate mit Apoptose induzierender Wirkung
PCT/EP2004/005593 WO2004108702A1 (de) 2003-06-05 2004-05-25 Indolderivate mit apoptose induzierender wirkung

Publications (1)

Publication Number Publication Date
MXPA05013121A true MXPA05013121A (es) 2006-03-17

Family

ID=43661564

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05013121A MXPA05013121A (es) 2003-06-05 2004-05-25 Derivados de indol con efecto de induccion de apoptosis.

Country Status (12)

Country Link
EP (1) EP1641777A1 (es)
JP (1) JP4878285B2 (es)
KR (1) KR101132599B1 (es)
CN (1) CN1816543B (es)
AU (1) AU2004245198B2 (es)
BR (1) BRPI0410998A (es)
CA (1) CA2526663C (es)
MX (1) MXPA05013121A (es)
NZ (1) NZ543853A (es)
RS (1) RS20050901A (es)
RU (1) RU2327696C2 (es)
WO (1) WO2004108702A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8217042B2 (en) 2005-11-11 2012-07-10 Zentaris Gmbh Pyridopyrazines and their use as modulators of kinases
EP1790342A1 (de) 2005-11-11 2007-05-30 Zentaris GmbH Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege
KR101400905B1 (ko) * 2005-11-11 2014-05-29 아에테르나 젠타리스 게엠베하 신규한 피리도피라진 및 키나제의 조절제로서의 이의 용도
RU2448703C2 (ru) * 2005-11-23 2012-04-27 Дзе Борд Оф Риджентс Оф Дзе Юниверсити Оф Техас Систем Онкогенное ras-специфичное цитотоксическое соединение и способы его применения
NZ596024A (en) * 2006-08-07 2013-07-26 Ironwood Pharmaceuticals Inc Indole compounds
JP2010511041A (ja) * 2006-11-28 2010-04-08 ジオファーム オンコロジー， インコーポレイテッド インジブリンを含むインドリル−３−グリオキシル酸誘導体の癌を処置するための単独またはさらなる薬剤との組み合わせでの使用
CN104958292B (zh) * 2008-10-16 2018-10-16 阵列生物制药公司 用于在治疗中增加凋亡的有丝分裂抑制剂
WO2012017325A2 (en) * 2010-07-19 2012-02-09 Procaps Sa Apparatus and process for encapsulating microparticles with liquid in soft gel capsules

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19814838C2 (de) * 1998-04-02 2001-01-18 Asta Medica Ag Indolyl-3-glyoxylsäure-Derivate mit Antitumorwirkung
TWI269654B (en) * 1999-09-28 2007-01-01 Baxter Healthcare Sa N-substituted indole-3-glyoxylamide compounds having anti-tumor action
DE19962300A1 (de) * 1999-12-23 2001-06-28 Asta Medica Ag Substituierte N-Benzyl-Indol-3-yl-glyoxylsäure-Derivate mit Antitumorwirkung
IT1318641B1 (it) * 2000-07-25 2003-08-27 Novuspharma Spa Ammidi di acidi 2-(1h-indol-3-il)-2-oxo-acetici ad attivita'antitumorale.
DE10037310A1 (de) * 2000-07-28 2002-02-07 Asta Medica Ag Neue Indolderivate und deren Verwendung als Arzneimittel
WO2003022280A2 (en) * 2001-09-13 2003-03-20 Synta Pharmaceuticals Corp. 3-glyoxlylamideindoles for treating cancer

Also Published As

Publication number Publication date
BRPI0410998A (pt) 2006-07-04
KR101132599B1 (ko) 2012-06-21
CN1816543A (zh) 2006-08-09
RU2006100022A (ru) 2006-05-27
JP2007523850A (ja) 2007-08-23
AU2004245198B2 (en) 2009-04-23
CA2526663C (en) 2011-07-19
EP1641777A1 (de) 2006-04-05
CA2526663A1 (en) 2004-12-16
CN1816543B (zh) 2011-01-19
NZ543853A (en) 2009-09-25
AU2004245198A1 (en) 2004-12-16
RS20050901A (en) 2007-12-31
JP4878285B2 (ja) 2012-02-15
KR20060034230A (ko) 2006-04-21
WO2004108702A1 (de) 2004-12-16
RU2327696C2 (ru) 2008-06-27

Similar Documents

Publication Publication Date Title
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
HK1096392A1 (en) Substituted heterocycles
GEP20084520B (en) Use of retinyl derivatives and compositions thereof for treating ophthalmic diseases
SG151327A1 (en) Deazapurines useful as inhibitors of janus kinases
ATE470443T1 (de) Indol-1-yl-essigsäurederivate
MX349787B (es) Formas de dosis oral que incluyen un agente antiplaqueta y un inhibidor de ácido.
WO2007127273A3 (en) Methods and compositions for altering cell function
WO2007002836A3 (en) Methods and compositions for the prevention and treatment of kidney disease
MXPA06012143A (es) Arilsulfonamidas y usos relacionados con las mismas.
UA108878C2 (ru) Ингибиторы протеинтирозинкиназной активности
TW200728295A (en) Benzochromene derivatives
MXPA04001256A (es) Productos de combinacion de derivados de propanolamina aril substituidos con otros ingredientes activos y su uso.
ZA201000581B (en) 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6-carboxamide and 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]-diazepine-7-carboxamide derivatives,preparation and therapeutic use thereof
MXPA05013121A (es) Derivados de indol con efecto de induccion de apoptosis.
DE50310038D1 (de) Hemmstoffe der urokinase, ihre herstellung und verwendung
EP1812112A4 (en) CHEMICAL COMPOUNDS
MXPA05008902A (es) Soluciones de drogas en mentol.
TW200504051A (en) Novel acridine derivatives and their use as medicaments
JO2666B1 (en) Use of agomelatine for medications to treat bilateral mental disorders
UA86021C2 (ru) Производные индола с эффектом, который индуцирует апоптоз
WO2005018569A3 (en) Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin modulating agent for the treatment of neoplasia
TW200603791A (en) Compounds and compositions as cathepsin S inhibitors
MY150436A (en) 1-oxo-isoindoline-4-carboxamide and 1-oxo-1,2,3,4-tetrahydroisoquinoline-5-carboxamide derivatives, preparation and therapeutic use thereof
WO2007012066A3 (en) TRUNCATED OXIDIZED THYMOSIN β4 AND DERIVATIVES THEREOF
NO20060045L (no) Indolederivater med apoptoseinduserende effekt

Legal Events

Date Code Title Description
FG Grant or registration